6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data